Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 27, 2026
Bank of Montreal (BMO) Prepares for Q2 2026 Earnings Release on May 27

Bank of Montreal (BMO) Prepares for Q2 2026 Earnings Release on May 27

Key Takeaways

  • Bank of Montreal is scheduled to report second quarter 2026 results on May 27, 2026, covering the period ended April 30, 2026.
  • Analysts expect adjusted earnings per share of approximately $2.80.
  • Investors will focus on net interest income trends, wealth management performance, and capital ratios such as Common Equity Tier 1 (CET1).
  • Recent acquisition activity, including Burgundy Asset Management, may influence wealth management results.
  • Guidance on loan growth, expense management, and credit quality will be closely monitored.
  • Historical stock reactions to earnings have varied based on beats or misses relative to consensus estimates.

Earnings Context and Why This Report Matters

Bank of Montreal reports earnings on a fiscal calendar ending October 31, with quarters aligned to January 31, April 30, July 31, and October 31. The second quarter 2026 results arrive amid a stable Canadian banking environment and ongoing integration of recent acquisitions. Strong performance in prior periods has supported revenue growth, while investors track how the bank navigates interest rate dynamics and client activity in personal, commercial, and wealth segments. This report offers an early look at fiscal 2026 momentum and potential updates to full-year expectations.

Earnings Expectations

Consensus estimates point to adjusted earnings per share near $2.80 for the quarter. Revenue is anticipated to reflect steady net interest income supported by loan volumes, alongside growth in fee-based wealth management income. Key areas of focus include the Common Equity Tier 1 (CET1) ratio, which measures capital strength, and any commentary on operating expenses following efficiency initiatives. Historical patterns show the stock often reacts to deviations from these expectations, particularly around credit loss provisions and deposit growth. Company guidance from prior quarters emphasized measured loan expansion and disciplined cost control. I also checked this using Tickeron’s AI Screener to see how BMO compares to peers in the sector.

Market Reaction and Investor Sentiment

Sentiment heading into the report remains measured, with attention on broader interest rate outlooks and Canadian economic indicators. Traders often position ahead of the release, watching for any pre-earnings volatility. Positive surprises in earnings or guidance have historically supported share price gains, while shortfalls can lead to near-term pressure. Key risk factors include potential shifts in credit demand and competitive pressures in retail banking.

Forward Outlook and Key Factors to Monitor

Following the release, investors will assess any updates to full-year guidance on earnings growth and capital return plans. Loan origination trends across personal and commercial lines will signal demand strength, while wealth management results may reflect market conditions and acquisition contributions.

Expense discipline remains a priority as the bank advances operational efficiencies. Credit quality metrics, including provisions for credit losses, will indicate the health of the loan portfolio amid evolving economic conditions.

Broader industry dynamics, such as regulatory developments in Canada and the United States, could also shape the outlook. The bank’s ability to maintain a robust CET1 ratio while supporting growth initiatives will be a recurring theme in future updates.

Enhancing Analysis with Tickeron’s AI Screener

In my research process, I often rely on Tickeron’s AI Screener to quickly filter stocks and ETFs by technical patterns, fundamentals, trends, and volatility. It allows customizable scans across industries, market caps, and performance metrics to spot ideas or compare opportunities more efficiently than manual methods. This tool has proven helpful for gaining additional context around names like BMO ahead of earnings. AI Screener

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BMO

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


BMO in upward trend: price may jump up because it broke its lower Bollinger Band on September 30, 2026

BMO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 41 cases where BMO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 68%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMO advanced for three days, in 211 of 387 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.

The Aroon Indicator entered an Uptrend today. In 153 of 336 cases where BMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 46%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMO as a result. In 36 of 65 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.

The Moving Average Convergence Divergence Histogram (MACD) for BMO turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 20 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 43%.

BMO moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 3 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 21, placing this stock slightly worse than average.

The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. BMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.982) is normal, around the industry mean (1.866). BMO has a moderately high P/E Ratio (19.746) as compared to the industry average of (14.888). Projected Growth (PEG Ratio) (1.518) is also within normal values, averaging (2.139). Dividend Yield (0.028) settles around the average of (0.026) among similar stocks. P/S Ratio (4.411) is also within normal values, averaging (3.867).

Notable companies

The most notable companies in this group are JPMorgan Chase & Co (NYSE:JPM), Bank of America Corp (NYSE:BAC), HSBC Holdings PLC (NYSE:HSBC), Wells Fargo & Co (NYSE:WFC), Citigroup (NYSE:C), Barclays PLC (NYSE:BCS).

Industry description

Major banks are among the biggest companies in the world, often times with global reach and market capitalizations in the multi-billions. Large banks often have multiple arms spanning different disciplines, from deposits, to investment banking, to wealth management and insurance. The biggest banks often have key competitive advantages over smaller players in the industry in terms of brand recognition, cost of capital, and efficiency. Think J.P. Morgan, Bank of America, Wells Fargo, and Citigroup.

Market Cap

The average market capitalization across the Major Banks Industry is 206.84B. The market cap for tickers in the group ranges from 1.04M to 894.72B. JPM holds the highest valuation in this group at 894.72B. The lowest valued company is BACRP at 1.04M.

High and low price notable news

The average weekly price growth across all stocks in the Major Banks Industry was -1%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 14%. FRBT experienced the highest price growth at 3%, while BBVA experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the Major Banks Industry was 17%. For the same stocks of the Industry, the average monthly volume growth was 49% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 68
P/E Growth Rating: 33
Price Growth Rating: 48
SMR Rating: 4
Profit Risk Rating: 21
Seasonality Score: 52 (-100 ... +100)
View a ticker or compare two or three
BMO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a major bank

Industry MajorBanks

Industry
Major Banks
Address
129 rue Saint Jacques
Phone
+1 877 225-5266
Employees
53000
Web
https://www.bmo.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
I've always appreciated how Mastercard (MA) maintains a commanding position in the global payments industry, processing transactions across 3.4 billion cards at 150 million merchant locations worldwide. The network effects here create a formidable moat—increased adoption by issuers, acquirers, and consumers just reinforces its dominance. What stands out to me is how Mastercard is evolving beyond a pure processor into a services-first platform. Value-added services (VAS)—covering cybersecurity, data analytics, and consulting—are now approaching 40% of revenues and growing at double the rate of traditional payments.